OPRX OptimizeRx Corp

OptimizeRx to Participate in Upcoming Investor Conferences 

OptimizeRx to Participate in Upcoming Investor Conferences 

WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 

  • RBC Capital Markets Global Healthcare Conference, New York City, May 14 – 15, 2024
  • B.Riley Securities 24th Annual Institutional Investor Conference, Beverly Hills, May 22 – 23, 2024
  • Stifel Cross Sector Insight Conference, Boston, June 4 – 5, 2024
  • William Blair & Co. Annual Growth Stock Conference, Chicago, June 4 – 6, 2024
  • The Citizens JMP Medical Devices and Healthcare Services Forum, Boston, June 20, 2024

Conference Details: 

RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 15, 2024
Location:InterContinental Barclay



B. Riley Securities 24th, Annual Institutional Investor Conference
Date: Thursday, May 23, 2024
Location:The Beverly Hilton in Beverly Hills



Stifel Cross Sector Insight Conference
Date: Tuesday, June 4, 2024
Location:The InterContinental Hotel Boston



William Blair & Co. Annual Growth Stock Conference
Date: Wednesday, June 5, 2024
Location:Loews Chicago Hotel



The Citizens JMP Medical Devices and Healthcare Services Forum
Date: Thursday, June 20, 2024
Location:Boston Harbor Hotel
  

To request a meeting or for more details about the conferences please reach out to your institutional contact.

About OptimizeRx 

OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels, OptimizeRx helps life sciences organizations engage and support their customers.

For more information, follow the Company on ,  or visit .  

Important Cautions Regarding Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

OptimizeRx Contact  

Andy D’Silva, SVP Corporate Finance 

 

Media Relations Contact  

Dilma Bennett, Media Relations Manager 

 

Investor Relations Contact 

Ashley Robinson 

LifeSci Advisors, LLC 

 



EN
06/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Reports First Quarter 2024 Financial Results

OptimizeRx Reports First Quarter 2024 Financial Results Q1 revenue of $19.7 million, increasing 51% year-over-yearQ1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%Won 9 DAAP deals during Q1 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period. Financial Highli...

 PRESS RELEASE

OptimizeRx to Participate in Upcoming Investor Conferences 

OptimizeRx to Participate in Upcoming Investor Conferences  WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:  RBC Capital Markets Global Healthcare Conference, New York City, May 14 – 15, 2024B.Riley Securities 24th Annual Institutional Investor Conference, Beverly Hills, May 22 – 23, 2024Stifel Cross Sector I...

 PRESS RELEASE

OptimizeRx Provides Business Update and Sets First Quarter 2024 Confer...

OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET 1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) an...

 PRESS RELEASE

OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) R...

OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024. As a company that provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures t...

 PRESS RELEASE

OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial ...

OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results Q4 revenue of $28.4 million, increasing 44% year-over-yearQ4 gross profit increased 43% year-over-year to $17.8 million with gross margins coming in at 63% for both periodsAcquired Healthy Offers, Inc. (dba Medicx Health), a leading healthcare consumer-focused omnichannel marketing and analytics company that significantly expands our footprint with consumers and patientsMeaningfully increased our DAAP footprint: 24 DAAP deals in 2023 compared to six deals in 2022 WALTHAM, Mass., April 16, 2024 (GLOBE NE...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch